Desmoid fibromatosis of extremity
Conditions
Interventions
Control group:Simple operation group
Experimental group:Surgery combined with anlotinib
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
8 Years to 58 Years
Inclusion criteria
Inclusion criteria: 1. Patients who were pathologically diagnosed as fibromatosis in West China Hospital and whose tumors were located in the extremities (including shoulder and hip); 2. Clinical symptoms (swelling pain, nerve damage or functional limitation, etc.) or disease progression (MRI examination indicated that the tumor grew 10% within 3 months).
Exclusion criteria
Exclusion criteria: 1. Patients who have received chemotherapy with other targeted drugs or cytotoxic drugs; 2. Patients who are allergic to anlotinib or have contraindications to the use of anlotinib or cannot tolerate the side effects of anlotinib.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local tumor recurrence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complications of surgery;Side effects of Anlotinib; | — |
Countries
China
Contacts
Public ContactDuan Hong
West China Hospital, Sichuan University
Outcome results
None listed